Butyrate ameliorates colorectal cancer through regulating intestinal microecological disorders

Anticancer Drugs. 2023 Feb 1;34(2):227-237. doi: 10.1097/CAD.0000000000001413. Epub 2023 Oct 24.

Abstract

The occurrence and progression of colorectal cancer (CRC) are closely related to intestinal microecological disorders. Butyrate, the representative of short chain fatty acids, possess anti-inflammatory and antioxidant effects, and its antitumor effect has been gradually paid attention to. In this study, azoxymethane/dextran sodium sulfate induced mouse CRC model was used to explore the role and mechanism of butyrate in regulating colon cancer and its intestinal microecological balance. Outcomes exhibited that butyrate alleviated weight loss, disease activity index, and survival in CRC mice and inhibited tumor number and progression. Further research revealed that butyrate restrained the aggregation of harmful while promoting the colonization of beneficial flora, such as Actinobacteriota, Bifidobacteriales and Muribaculacea through 16S rDNA sequence analysis. This study confirmed that butyrate can ameliorate CRC by repairing intestinal microecology, providing ideas and evidence for chemical prophylactic agents, such as butyrate to remedy tumors and regulate tumor microbiota.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azoxymethane / adverse effects
  • Butyrates / adverse effects
  • Colonic Neoplasms*
  • Colorectal Neoplasms* / pathology
  • Dextran Sulfate / adverse effects
  • Disease Models, Animal
  • Mice
  • Mice, Inbred C57BL

Substances

  • Butyrates
  • Azoxymethane
  • Dextran Sulfate